April 2025
Published: 01 Apr 2025
Author: Precedence Research
Eli Lilly and Company (LLY) announced that its LillyDirect digital healthcare platform has been expanded to improve access to care for Alzheimer's disease for the millions of Americans afflicted. Essentially, the platform connects patients to independent in-person or telehealth providers to combat the problems associated with delayed diagnosis and limited access to specialized care. The purpose of the expansion is to relieve the pressure on the healthcare system by creating more efficient avenues to diagnosis and management through partnerships with independent healthcare delivery organizations. Many millions of Americans live with the condition but have yet to receive a formal diagnosis.
The U.S. healthcare system must improve its ability to diagnose and manage Alzheimer's disease in light of increasing incidence rates of the disease. In general, some delays in diagnosis measure more than one year of challenge, often exacerbated in rural and underprivileged areas, where patients must travel long distances to see trained neurologists. Approximately, more than 50 miles each way to see a neurologist for about 20% of Medicare beneficiaries. On average, the duration between the onset of symptoms and diagnosis may be two years or more to render a formal diagnosis, adding to the whole spectrum of difficulty securing early intervention to enhance patient outcomes. Urgency regarding early diagnosis through biomarker tests is fundamental to applying intervention strategies and treatment that may alter the tempo of the disease. The enhanced LillyDirect platform aims to mitigate that dilemma by facilitating access to diagnostics and care pathways for thousands of Americans-giving them a fighting chance to progress from mild through moderate or severe stages of Alzheimer's disease every day.
LillyDirect has moved from its mail-order pharmacy option for Lilly medicines to education and connections to independent healthcare providers who see patients with expertise in Alzheimer's care. With the tools now integrated into the platform, patients can find local, office-based clinicians who are familiar with diagnosing and treating Alzheimer's disease. LillyDirect has partnered with Synapticure, an independent provider specializing in neurodegenerative care, offering telehealth options with live video visits, prior authorization support, broad insurance coverage, 24-hour access, ongoing medication and care management, and behavioral health support. Within two days of inquiry, the platform guarantees the patient access to a care navigator and an appointment with a neurologist proficient in Alzheimer's care within two weeks.
Alzheimer's patients deserve better care, for which Lilly is now expanding its platform. The platform will assist patients in identifying and accessing additional independent specialized care capacity in collaboration with their existing care team. Dr. David Hyman, Lilly's Chief Medical Officer, stated that early diagnosis with early care can change the quality of life for the person with Alzheimer's. Inclusion of Alzheimer's resources on LillyDirect aligns with the company's mission to empower patients to find appropriate care.
LillyDirect, a platform for Alzheimer's care, has hit the international scene, commencing with the land down under, Australia. The platform provides educational materials, links to independent health professionals, and support for general health and well-being. The patient experience is enhanced, quite deliberately, by not including any information about Lilly medicines. Lilly will introduce additional markets later this year, reiterating the commitment to supporting patients on a global scale. The extended LillyDirect platform will aim to cross over any healthcare system gaps and provide hope for the patients and families who walk through the journey of Alzheimer's disease.
April 2025
April 2025
April 2025
April 2025